Vimarsana
Biggest News Aggregation in the World

Jamese Bradner News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jamese Bradner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jamese Bradner Today - Breaking & Trending Today

Amgen's potential Ozempic competitor sends stock up 13% - Vimarsana News

Amgen's potential Ozempic competitor sends stock up 13%

Amgen's potential weight loss drug is heading to a larger phase 3 trial

Source: qz.com
CCCC Stock Price | C4 Therapeutics Inc. Stock Quote (U.S.: Nasdaq) - Vimarsana News

CCCC Stock Price | C4 Therapeutics Inc. Stock Quote (U.S.: Nasdaq)

CCCC | Complete C4 Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Reviewing Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Syros Pharmaceuticals (NASDAQ:SYRS) - Vimarsana News

Reviewing Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Syros Pharmaceuticals (NASDAQ:SYRS)

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) and Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership. Volatility & Risk Calliditas Therapeutics AB (publ) […]

StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Vimarsana News

StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) in a research report report published on Thursday. The firm issued a hold rating on the stock. Several other research firms have also weighed in on SYRS. JMP Securities reduced their price objective on shares of Syros Pharmaceuticals from $16.00 to $15.00 in […]

Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com - Vimarsana News

Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) in a report published on Thursday. The brokerage issued a hold rating on the stock. A number of other equities analysts have also recently weighed in on the stock. JMP Securities reduced their price target on shares of Syros Pharmaceuticals from $16.00 to […]

Source: wkrb13.com